- Home
- ZLAB vs UTF Comparison
ZLAB vs UTF Comparison
Compare ZLAB & UTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- UTF
- Stock Information
- Founded
- ZLAB 2013
- UTF 2004
- Country
- ZLAB China
- UTF United States
- Employees
- ZLAB N/A
- UTF N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- UTF Finance Companies
- Sector
- ZLAB Health Care
- UTF Finance
- Exchange
- ZLAB Nasdaq
- UTF Nasdaq
- Market Cap
- ZLAB 3.0B
- UTF 2.5B
- IPO Year
- ZLAB 2017
- UTF N/A
- Fundamental
- Price
- ZLAB $26.67
- UTF $24.96
- Analyst Decision
- ZLAB Strong Buy
- UTF
- Analyst Count
- ZLAB 4
- UTF 0
- Target Price
- ZLAB $52.50
- UTF N/A
- AVG Volume (30 Days)
- ZLAB 1.1M
- UTF 266.0K
- Earning Date
- ZLAB 11-12-2024
- UTF 01-01-0001
- Dividend Yield
- ZLAB N/A
- UTF 8.21%
- EPS Growth
- ZLAB N/A
- UTF N/A
- EPS
- ZLAB N/A
- UTF N/A
- Revenue
- ZLAB $355,748,000.00
- UTF N/A
- Revenue This Year
- ZLAB $48.50
- UTF N/A
- Revenue Next Year
- ZLAB $47.37
- UTF N/A
- P/E Ratio
- ZLAB N/A
- UTF N/A
- Revenue Growth
- ZLAB 35.01
- UTF N/A
- 52 Week Low
- ZLAB $13.48
- UTF $18.15
- 52 Week High
- ZLAB $36.60
- UTF $24.49
- Technical
- Relative Strength Index (RSI)
- ZLAB 41.98
- UTF 41.45
- Support Level
- ZLAB $27.74
- UTF $24.75
- Resistance Level
- ZLAB $32.15
- UTF $25.79
- Average True Range (ATR)
- ZLAB 1.36
- UTF 0.32
- MACD
- ZLAB -0.64
- UTF -0.02
- Stochastic Oscillator
- ZLAB 3.15
- UTF 12.04
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About UTF Cohen & Steers Infrastructure Fund Inc
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.